MA50189A - Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci - Google Patents

Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci

Info

Publication number
MA50189A
MA50189A MA050189A MA50189A MA50189A MA 50189 A MA50189 A MA 50189A MA 050189 A MA050189 A MA 050189A MA 50189 A MA50189 A MA 50189A MA 50189 A MA50189 A MA 50189A
Authority
MA
Morocco
Prior art keywords
abiraterone
administering
processes
forming
same
Prior art date
Application number
MA050189A
Other languages
English (en)
Inventor
Urvi Gala
Dave Miller
Original Assignee
Dispersol Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dispersol Technologies Llc filed Critical Dispersol Technologies Llc
Publication of MA50189A publication Critical patent/MA50189A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050189A 2017-09-22 2018-09-20 Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci MA50189A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762562081P 2017-09-22 2017-09-22

Publications (1)

Publication Number Publication Date
MA50189A true MA50189A (fr) 2021-05-19

Family

ID=65808544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050189A MA50189A (fr) 2017-09-22 2018-09-20 Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci

Country Status (10)

Country Link
US (1) US20190091339A1 (fr)
EP (1) EP3684371A4 (fr)
JP (2) JP2020534320A (fr)
KR (1) KR20200064993A (fr)
CN (1) CN111107852A (fr)
AU (1) AU2018335391A1 (fr)
CA (1) CA3075095A1 (fr)
IL (1) IL273125A (fr)
MA (1) MA50189A (fr)
WO (1) WO2019060525A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113825514A (zh) * 2019-03-18 2021-12-21 分散技术有限责任公司 阿比特龙-环状寡聚体药物制剂及其形成和施用方法
CN110141556B (zh) * 2019-06-24 2021-07-13 李建恒 一种阿比特龙包合物片剂及其制备方法
US20210128536A1 (en) * 2019-11-01 2021-05-06 Dispersol Technologies, Llc Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof
AU2020384948B2 (en) * 2019-11-14 2025-11-06 Suven Life Sciences Limited Amorphous pharmaceutical compositions of abiraterone acetate
US20220401579A1 (en) * 2019-11-30 2022-12-22 Dispersol Technologies, Llc Inclusion complexes of pharmaceuticals and cyclic oligomers
KR102363026B1 (ko) * 2019-12-26 2022-02-16 보령제약 주식회사 아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 전립선암 예방 또는 치료용 약학적 조성물
JP2023553010A (ja) 2020-12-03 2023-12-20 バテル・メモリアル・インスティテュート 非ウイルス性送達のためのポリマーナノ粒子およびdnaナノ構造組成物ならびに方法
EP4320233A4 (fr) 2021-04-07 2025-08-13 Battelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990445C (fr) * 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Melange thermocinetique pour des applications pharmaceutiques
US9040080B2 (en) * 2008-10-21 2015-05-26 Southwest Research Institute Processing of heat-sensitive active agents
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ,インク. 前立腺癌を処置するための新規な組成物及び方法
CA2856646C (fr) * 2011-11-30 2020-01-14 Astrazeneca Ab Traitement combine du cancer
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (fr) * 2012-07-11 2014-01-16 Sandoz Ag Stabilité d'oxydation d'acétate d'abiratérone
JP2016514707A (ja) * 2013-03-15 2016-05-23 アイシューティカ インク.Iceutica Inc. アビラテロン酢酸エステル製剤
WO2015032873A1 (fr) * 2013-09-06 2015-03-12 Synthon B.V. Compositions pharmaceutiques à charge élevée comprenant de l'acétate d'abiratérone
WO2016051368A1 (fr) * 2014-10-01 2016-04-07 Mylan Laboratories Ltd Complexe d'empagliflozine amorphe et d'une cyclodextrine
WO2017037647A1 (fr) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Compositions pharmaceutiques stables d'abiratérone

Also Published As

Publication number Publication date
EP3684371A4 (fr) 2021-05-19
EP3684371A1 (fr) 2020-07-29
KR20200064993A (ko) 2020-06-08
AU2018335391A1 (en) 2020-03-26
US20190091339A1 (en) 2019-03-28
WO2019060525A1 (fr) 2019-03-28
CA3075095A1 (fr) 2019-03-28
JP2023182674A (ja) 2023-12-26
CN111107852A (zh) 2020-05-05
IL273125A (en) 2020-04-30
JP2020534320A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
MA50189A (fr) Formulations pharmaceutiques d'oligomère cyclique et d'abiratérone et procédés de formation et d'administration de celles-ci
IL275704A (en) Pharmaceutical formulation for oral administration containing cannabinoids and poloxamer
EP3356522A4 (fr) Compositions contenant un exosome chargé d'une protéine, et procédés de préparation et d'administration correspondants
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
EP3946547A4 (fr) Dispositifs et procédés d'administration de compositions pharmaceutiques
EP3380525A4 (fr) Formulations pharmaceutiques et leurs procédés d'utilisation
IL284733A (en) Pharmaceutical delivery compositions and uses thereof
EP3528787A4 (fr) Formulations pharmaceutiques et leurs procédés de préparation
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EP3318282A4 (fr) Vecteur d'administration de médicament, et composition le contenant
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
EP3526195A4 (fr) Sulfoxyalkyle organonitro, composés apparentés et compositions pharmaceutiques destinées à être utilisées en médecine
EP3773900A4 (fr) Analogues d'hinokitiol, procédés de préparation et compositions pharmaceutiques de ceux-ci
EP3442542A4 (fr) Nanoparticules, formes posologiques à libération contrôlée et procédés d'administration d'un agent immunothérapeutique
EP3643353A4 (fr) Robot d'administration de médicament
MA55015A (fr) Formulations pharmaceutiques
EP3694590A4 (fr) Systèmes d'administration de médicaments et procédés associés
EP3773654C0 (fr) Compositions médicamenteuses polypharmaceutiques et méthodes associées
EP3982942A4 (fr) Procédés et compositions d'administration de médicament
IL285073B2 (en) Liquid concentrated pharmaceutical preparations of furosemide and methods of administering these preparations
EP3377043A4 (fr) Véhicules nanométriques déformables (dnvs) pour l'administration transmucosale et transdermique de médicaments à travers la barrière hémato-encéphalique
EP3452441A4 (fr) Dérivés d'acide alpha-truxillique et compositions pharmaceutiques associées
EP3801539A4 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine